TOKYO, June 10 Japan has no plans to halt sales
of Takeda Pharmaceutical Co's Actos diabetes drug, an
official at the nation's health ministry said on Friday, after
it was pulled from the market in France due to worries of a
possible cancer link.
France's drug safety authority suspended use of both Actos
and Competact -- which combines Actos and an older drug called
metformin -- on Thursday saying an official study had found they
appeared to slightly raise the risk of bladder cancer.
After France's move, the European Medicines Agency, based in
London, said it was reviewing all relevant data about the safety
of Actos and the possibility of a link to bladder cancer, but
was not recommending any changes in use in the meantime.
Takeda officials said earlier that U.S. regulators had not
signalled any intention to request a recall of the blockbuster
product, which had global sales of 387.9 billion yen ($4.8
billion) in the year ended on March 31, accounting for 27
percent of Takeda's revenues.
Shares of Takeda were down 2.3 percent at 3,690 yen by the
midday break in Tokyo, underperforming a 1.3 percent rise in the
Nikkei average .
($1 = 80.305 Japanese Yen)
(Reporting by James Topham)